Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2Unknown 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 112Recurrence 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Neoplasms 14Neoplasms, Plasma Cell 13Leukemia 10Lymphoma, Non-Hodgkin 8Lymphoma 8Leukemia, Myeloid, Acute 8Carcinoma, Non-Small-Cell Lung 8Lymphoma, Large B-Cell, Diffuse 7Burkitt Lymphoma 7Vomiting 6Prostatic Neoplasms 6Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Nausea 5Lung Neoplasms 5Pancreatic Neoplasms 3Lymphoma, Follicular 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Neoplasms 3Hematologic Diseases 3Glioblastoma 3Amyloidosis 3Smoldering Multiple Myeloma 2Renal Insufficiency 2Oligodendroglioma 2Myelodysplastic Syndromes 2

Interventions

Pemetrexed 8pembrolizumab 6Cisplatin 6LMB-100 3Carboplatin 3Radiosurgery 2Plicamycin 2Dexamethasone 2Cryotherapy 2vandetanib 1tremelimumab 1tocilizumab 1rebastinib 1pevonedistat 1perflutren 1nintedanib 1iodixanol 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1durvalumab 1defactinib 1anetumab ravtansine 1amatuximab 1alvocidib 1aldesleukin 1Vinorelbine 1Sulfur Hexafluoride 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Mesothelioma × Dexamethasone × Clear all
NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Takeda

Phase 1/2 Terminated
61 enrolled 29 charts
BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT04840615 2024-02-02

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
2 enrolled 14 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡